The United States Food and Drug Administration (FDA) has granted United Kingdom-based AstraZeneca and United States-based Merck a New Drug Application (NDA) and priority review for the MEK 1/2 inhibitor Selumetinib as a potential new medicine for paediatric patients aged three years and older with neurofibromatosis (NF1) type one and symptomatic, inoperable plexiform neurofibromas (PFs), it was reported on Friday.
This is the first acceptance of a regulatory submission for an oral MEK 1/2 monotherapy for patients with NF1, a rare and incurable genetic condition. A Prescription Drug User Fee Act (PDUFA) date is scheduled for the second quarter of 2020.
This regulatory submission was based on positive results from the National Cancer Institute (NCI) Cancer Therapy Evaluation Program (CTEP)-sponsored SPRINT Phase two Stratum one trial. An objective response rate (ORR) was achieved in 66% of paediatric patients with neurofibromatosis type 1 and symptomatic, inoperable PNs (n=33/50 patients) when treated with selumetinib as a twice-daily oral monotherapy. ORR was defined as the percentage of patients with a confirmed complete or partial response of greater than 20% tumour volume reduction.
AstraZeneca and Merck have a strategic collaboration agreement to co-develop and co-commercialize selumetinib globally.
Biotheus expands strategic collaboration with Hansoh Pharmaceutical Group Co
Ionis Pharmaceuticals announces positive results from phase two ION224 study
Prolytix partners with Allumiqs
10x Genomics begins shipping first two products powered by the GEM-X technology architecture
Poseida Therapeutics' P-BCMA-ALLO1 receives US FDA Orphan Drug Designation
AstraZeneca expands rare disease pipeline with Amolyt Pharma acquisition
PureTech's LYT-200 granted FDA orphan drug designation for acute myeloid leukemia treatment
AstraZeneca launches Phase III THARROS trial for BREZTRI in COPD to assess cardiopulmonary outcomes
PepGen receives FDA designations for Duchenne muscular dystrophy therapy
Pfizer's PREVENAR 20 gains European Commission approval for paediatric pneumococcal vaccine
Sumitomo Pharma Canada announces ORGOVYX (relugolix) prostate cancer drug availability in Canada
Ratio Therapeutics reaches expanded manufacturing agreement with PharmaLogic